Business Description
Compare
Compare
Traded in other countries / regions
YP2A.GermanyBLRX.IsraelBLRX.USA IPO Date
2008-02-13Description
BioLine Rx Ltd is a clinical-stage biopharmaceutical development company with a strategic focus on oncology. Its development and commercialization pipeline consists of two clinical-stage therapeutic candidates - Motixafortide, a novel peptide for the treatment of solid tumors, hematological malignancies and stem cell mobilization, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, it has an off- strategy, a legacy therapeutic product called BL-5010 for the treatment of skin lesions.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 4.15 | |||||
| Equity-to-Asset | 0.67 | |||||
| Debt-to-Equity | 0.24 | |||||
| Debt-to-EBITDA | -0.55 | |||||
| Piotroski F-Score | 1/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 42.3 | |||||
| 3-Year EPS without NRI Growth Rate | 43.9 | |||||
| 3-Year FCF Growth Rate | 39.6 | |||||
| 3-Year Book Growth Rate | -34.4 |
Momentum Rank
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.87 | |||||
| Quick Ratio | 4.87 | |||||
| Cash Ratio | 4.78 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -75.3 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -42.37 | |||||
| ROA % | -32.65 | |||||
| ROIC % | -113.25 | |||||
| ROC (Joel Greenblatt) % | -1057.3 | |||||
| ROCE % | -34.6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.87 | |||||
| Price-to-Tangible-Book | 1.56 | |||||
| EV-to-EBIT | -0.21 | |||||
| EV-to-EBITDA | -0.22 | |||||
| EV-to-FCF | -0.19 | |||||
| Price-to-Net-Current-Asset-Value | 1.72 | |||||
| Price-to-Net-Cash | 1.72 | |||||
| Earnings Yield (Greenblatt) % | -476.19 |
How BioLine Rx Ltd (BLNEF) Makes Its Money
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:BLNEF
Peter Lynch Chart
Performance
Dividend
Log
Annualized Return %
Total Annual Return %
Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | 0 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR ($) | 0 | ||
| 20-Day SMA ($) | 0 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range ($) | 0.86 - 0.86 | ||
| Shares Outstanding (Mil) | 105.06 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
BioLine Rx Ltd Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||
BioLine Rx Ltd Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
BioLine Rx Ltd Frequently Asked Questions
What is BioLine Rx Ltd(BLNEF)'s stock price today?
The current price of BLNEF is $0.86. The 52 week high of BLNEF is $0.86 and 52 week low is $0.86.
When is next earnings date of BioLine Rx Ltd(BLNEF)?
The next earnings date of BioLine Rx Ltd(BLNEF) is 2023-05-11 Est..
Does BioLine Rx Ltd(BLNEF) pay dividends? If so, how much?
BioLine Rx Ltd(BLNEF) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
